Convection enhanced delivery to treat malignant recurrent spinal cord astrocytoma using ACNU and Temozolomide - CED to treat malignant recurrent spinal cord astrocytoma using ACNU and TMZ

Tominaga Teiji0 个研究点目标入组 15 人开始时间: 2019年3月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Clinically considered a spinal cord recurrent glioma. Radiographically, it is an intramedullary lesion, and originated from it. Spinal recurrent disseminated lesions of intracranial primary malignant gliomas such as cerebrum, cerebellum, brain stem (these cases need to have tissue diagnosis of the primary tumor) are targeted.

•1) have active duplicate cancer
•2) Merging of meningitis or pneumonia requiring treatment
•3) During pregnancy, women with the potential for pregnancy or breast-feeding
•4) Active inflammatory findings exist (CRP> 2.0)
•5) Severe liver dysfunction exists (GOT> 100 IU / l or GPT> 100 IU / l)
•6) Leukocytes (3000 / mm3) in which bone marrow dysfunction exists, Hemoglobin (8.0 g / dl), Platelets (10 x 10 4/mm3)
•7) Creatinine with renal failure (> 1.5 mg / dl)
•8) have bleeding diathesis
•9) Oral administration of anticoagulant or antiplatelet drug
•10) Psychosis or psychiatric symptoms are merged and it is judged difficult to participate in the exam
•11) Merging diabetes with poor control
•12) have a history of myocardial infarction within 3 months or have unstable angina
•13) have a history of pulmonary fibrosis or interstitial pneumonia

发起方

Tominaga Teiji